Pricing Log in Create free account

Aprea Therapeutics, Inc. (APRE) vs Karyopharm Therapeutics Inc. (KPTI)

Aprea Therapeutics, Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. Aprea Therapeutics, Inc. and Karyopharm Therapeutics Inc. are of similar size ($8.0M and $7.8M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −81.0%. Aprea Therapeutics, Inc. has the higher net margin (0.00% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Aprea Therapeutics, Inc. leads on 10 and Karyopharm Therapeutics Inc. on 5.

Valuation

Metric APRE KPTI Biotechnology median
P/E n/m n/m 8.50
P/S 108.58 0.08 9.71
P/B 0.81 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.77 n/m 0.64
EV/Sales (35.75) 1.34 9.21
Earnings yield (186.21%) (3,634.56%) (33.15%)
Free cash flow yield (39.30%) (580.28%) (25.50%)

Profitability

Metric APRE KPTI Biotechnology median
Gross margin 100.00% 95.89% 65.16%
Operating margin 0.00% (56.17%) 0.00%
Net margin 0.00% (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity (47.44%) 78.98% (56.36%)
Return on assets (41.30%) (207.90%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE KPTI Biotechnology median
Revenue growth (TTM) (80.99%) 6.81% 6.02%
EPS growth (last fiscal year) 17.87% (98.37%) 30.26%
Revenue growth, 5-year CAGR — 6.21% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 13.55 0.79 4.72
Net debt to EBITDA 1.11 (2.03) 0.96

Dividend

Metric APRE KPTI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric APRE KPTI Biotechnology median
Market cap 7.78m 7.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack